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Abstract
Background: Whilst evidence exists to support the use of single treatments such as orthoses and footwear, the
effectiveness of podiatry-led care as a complex intervention for patients with rheumatoid arthritis (RA) related
foot problems is unknown. The aim of this study was to undertake an exploratory randomised controlled parallel
arm clinical trial (RheumAFooT) to inform the design and implementation of a definitive trial and to understand
the potential benefits of this care.
Methods: Patients with a definite diagnosis of RA, stable drug management 3 months prior to entry, and a current
history of foot problems (pain, deformity, stiffness, skin or nail lesions, or footwear problems) were recruited
from a hospital outpatient rheumatology clinic and randomised to receive 12 months of podiatry treatment or no
care. The primary outcome was change in foot health status using the impairment/footwear (LFISIF) and activity
limitation/participation restriction (LFISAP) subscales of the Leeds Foot Impact Scale. Disease Activity Score
(DAS), Health Assessment Questionnaire (HAQ) score and walking speed (m/s) were also recorded.
Results: Of the 80 patients identified, 64 patients were eligible to participate in the pilot and 34 were recruited.
16 patients were randomised to receive podiatry led foot care and 18 received no care. Against a backdrop of
stable disease (DAS and HAQ scores), there was a statistically significant between group difference in the change
in foot health status for foot impairment (LFISIF) but not activity/participation (LFISAP) or function (walking speed)
over 12 months. In the podiatry arm, 1 patient declined treatment following randomisation (did not want
additional hospital visits) and 3 self-withdrew (lost to follow-up). Patients received an average of 3 consultations
for assessment and treatment comprising routine care for skin and nail lesions (n = 3), foot orthoses (n = 9),
footwear referral to the orthotist (n = 5), and ultrasound guided intra-articular steroid injection (n = 1).
Conclusion: In this exploratory trial patients were difficult to recruit (stable drug management and co-morbid
disease) and retain (lack of benefit/additional treatment burden) but overall the intervention was safe (no adverse
reactions). Twelve months of podiatry care maintained but did not improve foot health status. These observations
are important for the design and implementation of a definitive randomised controlled trial.
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Background
Rheumatoid arthritis (RA) is a long-term inflammatory
disease affecting about 1% of the population and is char-
acterised by joint inflammation, progressive joint destruc-
tion and increasing functional disability [1]. Cross
sectional studies in patients with established disease sug-
gest that foot problems occur in around 80–90% of
patients typically in the form of forefoot pain, stiffness,
deformity, skin pressure lesions such as callosities and
problems related to footwear fit and comfort [2,3]. In
early disease (typically < 2 years), active joint disease lead-
ing to foot pain and altered joint function may be prob-
lematic in about one-third of patients [4,5]. Overall, the
burden of foot disease in RA is substantial and impacts
negatively on health-related quality of life [4,6].
Treatment for RA aims to decrease and control pain and
stiffness, reduce or prevent cumulative joint damage, max-
imise physical function, and improve quality of life. Podi-
atrists are regarded as the expert on foot problems and are
well placed to assess, advise and treat patients with RA [7].
Expert opinion and clinical practice guidelines suggest
patients should be treated early in the disease with an
emphasis on treating biomechanical problems using cus-
tomised foot orthoses [7,8]. In established disease, typical
podiatry interventions such as orthoses, specialist foot-
wear, and debridement of callus aim to lessen foot pain
and improve function [9-11]. However, podiatry services
in UK rheumatology centres are scarce despite significant
unmet demand [12,13]. Indeed, a recent survey indicated
that unmet demand for chiropody or footwear was
reported in almost half (46%) of RA patients, and this
ranked the highest amongst requested services [13].
A recent systematic review suggests that RA patients are
likely to benefit from foot orthoses and specialist foot-
wear with little or no evidence of harm [14]. In contrast,
scalpel debridement for painful plantar callosities pro-
vides only short term pain relief for approximately 7 days.
The benefits and harm of foot surgery have not been
established as no randomised controlled trials (RCTs)
have been conducted [14]. In routine clinical practice the
podiatrist may play an important role in the larger and
more complex delivery of foot care for patients with RA
[15,2]. The Medical Research Council (MRC) framework
for evaluating complex interventions recommends a
phased approach through a continuum of increasing evi-
dence [17]. Since much of the pre-clinical work has
already been reported and components of podiatry inter-
vention are relatively well defined, the aim of this study
was to conduct an exploratory (phase II) RCT (RheumA-
FooT – Rheumatoid Arthritis Foot Trial) of podiatry-led
foot care in RA patients with foot problems. The trial was
designed to answer 2 specific questions; (1) what are the
key methodological features for a pragmatic RCT to eval-
uate the effectiveness of podiatry-led foot care in RA
patients with foot problems, and (2) how effective is this
intervention?
Methods
Ethical approval
Leeds (West) Local Research Ethics Committee, Leeds UK
(03/078) provided the ethical review and approval.
Patient involvement
A focus group was conducted with patients who had pre-
viously received podiatry care. Areas explored included
their expectations and experiences of podiatry care in the
local setting, as well as opinion on the mode and delivery
of care, those providing care and alternative experiences
including medical management, surgery and self-care.
Specific input was sought for the study design and ethical
implications, patient recruitment and involvement, and
development and use of study materials including con-
sent forms and information leaflets. Emerging themes and
key issues were identified, documented and summarised
in a debriefing session and the relevant findings incorpo-
rated into the phase II exploratory trial.
Participants
Participants were recruited to the study from the medical
and nurse-led rheumatology outpatient clinics at a single
secondary care centre (Leeds General Infirmary, Leeds,
UK). Patients were identified from new referrals to the
hospital podiatry service by clinicians. Patients were eligi-
ble for inclusion if they had a definite diagnosis of RA
(satisfying the 1987 American Rheumatism Association
revised criteria for RA [18]), were between 18–80 years of
age, were able to read and write English and had a current
history of foot problems with an impairment/footwear
subscale (LFISIF) score of ≥4 points on the Leeds Foot
Impact Scale [19]. Patients were also required to have sta-
ble drug management in the 3 months prior to recruit-
ment. Patients were excluded if they had received podiatry
treatment within the last 3 months, had foot problems
primarily related to other medical conditions such as dia-
betes mellitus and peripheral vascular disease, or had sig-
nificant complications with their RA placing them at risk
of foot ulceration or infection, especially those on bio-
logic and other immunosuppressant therapy.
Randomisation
Random allocation was performed by the Central Ran-
domisation Service based at the Northern and Yorkshire
Clinical Trials and Research Unit. The allocation was con-
ducted independently of the researcher undertaking the
outcome assessments. Consultations for those patients
randomised to receive podiatry were undertaken by clini-
cians blinded to the patient's inclusion in this study andBMC Musculoskeletal Disorders 2007, 8:109 http://www.biomedcentral.com/1471-2474/8/109
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patients were also instructed not to inform clinicians of
their involvement.
Interventions
The podiatry interventions were undertaken by a small
team of podiatry staff working in rheumatology outpa-
tients. The podiatrists were blinded to the patient's alloca-
tion to the intervention arm. Accordingly, the trial was a
pragmatic evaluation of current care where patients were
assessed, treated and followed-up according to need. Pre-
clinical work showed that the podiatrists delivered indi-
vidualised care comprising one or more treatments: foot
health advice including disease information, treatment
guidance and self-management strategies; prescription
footwear therapy and foot orthotic interventions includ-
ing customised and non-customised devices; palliative or
surgical treatments for nail disorders; palliative care for
non-ulcerated pressure-induced skin lesions including
corns and callosities; and maintenance of optimal tissue
viability for pre-ulcerative lesions and wound care man-
agement for ulcerative skin lesions. In some cases referrals
were made to other diagnostic services and specialists
including the rheumatologist, rheumatology nurse practi-
tioner, orthopaedic surgeon, physiotherapist, occupa-
tional therapist and orthotist. In this unit one podiatrist
working in a specialist role was trained to perform intra-
articular corticosteroid injections. Patients randomised to
the non-intervention arm did not receive foot care for the
12 month study period. Usual outpatient medical/nurse-
led care was maintained for both patient groups.
Outcomes
The primary outcome was the LFISIF subscale of the Leeds
Foot Impact Scale [19]. This was measured at 8, 4 and 0
weeks prior to treatment to establish a precise baseline
measure and repeated at 3, 6, 9 and 12 months following
the start of podiatry care. Secondary outcomes included
the activity limitation/participation restriction subscale of
the LFIS (LFISAP), the Disease Activity Score (DAS) using
28 joint counts, the Stanford Health Assessment Ques-
tionnaire score (HAQ) for functional disability, and walk-
ing speed (a quantitative measure of global function).
Demographics, disease characteristics and drug use were
also recorded at baseline. The type and frequency of podi-
atry care along with adverse effects were also monitored in
the podiatry intervention group.
Data analysis
The outcome data was analysed using SPSS 13.0 for Win-
dows. The main study outcomes were summarised as
mean (SD) or median (interquartile range) depending on
the distribution of the data. The preliminary evaluation of
the relative effectiveness of the podiatry intervention was
determined by comparing the change in primary outcome
between baseline and 12 months. Those patients who did
not receive the allocated intervention or were lost to fol-
low-up were invited to receive an evaluation at 12
months. If they declined their last available data was used
for analysis. The analysis was based on the Hodges-Leh-
man estimate of the median difference with 95% confi-
dence interval based on a two-sided Mann-Whitney U-
test.
Results
Patient involvement
Findings from the focus group showed that none of the
patients had received information about the role of the
podiatrist prior to referral. Expectations were described as
low, neutral, hesitant or hopeful. Patients expected to
receive nail care, treatment for hard skin or insoles based
on their understanding of chiropody treatment. Three-
quarters of patients had found their treatment helpful.
Those dissatisfied cited repeat use of ineffective treatments
such as insoles and footwear and delay of other subse-
quently more effective treatments such as joint injections
and orthopaedic foot surgery. Use of a non-intervention
arm was universally supported when presented among
other scenarios and 12 months was considered the opti-
mum time to evaluate the effects of treatment. Some
patients were aware that podiatry services were not widely
available in rheumatology clinics. Patients highlighted
potential recruitment and follow-up problems, especially
for patients in work, due to difficulties attending clinic for
additional non-medical treatments, especially when
expectations were low. The patients contributed to the
successful development of trial information including, for
example, the patient information leaflet.
Trial Profile
Eighty patients attending rheumatology outpatient clinics
were identified as potential participants. Twenty-nine
patients refused to participate, 6 patients did not meet the
inclusion criteria and one patient who required urgent
treatment for a foot ulcer was ineligible (Figure 1). Thirty-
four patients were randomly allocated to the podiatry
intervention (n = 16) and no podiatry intervention (n =
18) groups. In the podiatry group, 15 patients received the
allocated treatment and one declined immediately fol-
lowing allocation. In the no podiatry intervention group,
16 patients received the allocated intervention, 1 patient
declined immediately following allocation and 1 patient
withdrew. Numbers lost to follow up were 3 for the podi-
atry and 4 for the no podiatry intervention groups.
Demographic and clinical characteristics
The baseline characteristics of the patients by allocation
are shown in Table 1. Patients in the podiatry intervention
arm were younger and had a shorter disease duration,
lower disease activity and less functional disability but dif-
fered significantly only in terms of age (p = 0.03). PatientsBMC Musculoskeletal Disorders 2007, 8:109 http://www.biomedcentral.com/1471-2474/8/109
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were well matched for pharmacological management pro-
files. Foot pain on the LFIS subscale was similar but the
podiatry group experienced less foot-related disability and
walked faster although none of these baseline scores were
significantly different.
Primary outcome
There was a statistically significant between-group differ-
ence in the primary outcome (Table 2). However there
was no change from the baseline score in the podiatry
intervention group and a small deterioration in foot
impairment in the no podiatry group. Overall the effect
size was small and clinically unimportant.
Secondary outcomes
The LFISAP scores showed no change in both groups over
the 12 month study period (Table 2). Over the course of
12 months patients in both arms of the trial had stable
disease and no deterioration in functional disability as
evidenced by the DAS and HAQ scores respectively. Simi-
larly, walking speed was unchanged and no between
group differences were detected.
Podiatry treatment
The podiatry treatment records were not available for 1
patient. Three patients were assessed but no treatment
provided within the 12 months. Of these one was referred
back to the clinical nurse specialist in disease flare and a
second referred directly to the orthotist for orthoses and
footwear and to primary care for basic podiatry foot care.
Five patients received custom orthoses from the podiatrist
and were referred to the orthotist for specialist footwear.
Of these, 3/5 received one additional care episode com-
prising ultrasound-guided intra-articular corticosteroid
injection to the talonavicular joint, callus debridement,
and in-growing toenail care. Six patients received either a
simple insole (n = 1) or a custom orthosis (n = 5) as a sin-
gle intervention. There was no evidence of any adverse
reactions or side-effects to any of the interventions pro-
vided. Only 3 received routine follow-up. Of the 9
patients treated more than once in the 12 month study
period only 1 had continuous care.
Discussion
We undertook RheumAFooT as an exploratory phase II
trial of podiatry care for patients with RA. Important infor-
mation was gathered to inform the design and implemen-
tation of a definitive RCT. By controlling for potentially
significant confounders on the main outcome, particu-
larly pharmacological management and co-morbidity, we
encountered recruitment problems. The pragmatic design
revealed important problems for, (1) defining the start of
treatment, (2) variation in delivery of treatment and (3)
use of other medical and allied health services. However,
involving a patient focus group beneficially facilitated the
design and implementation of the trial especially with
Trial profile and participant flow Figure 1
Trial profile and participant flow.
Excluded (n=46) 
Not meeting inclusion criteria (n=16) 
Refused to participate (n=29) 
Other reasons (required urgent foot care 
n=1) 
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Did not receive allocated intervention (declined 
following allocation) (n=1) 
 
Allocated to non podiatry intervention (n=18)
Received allocated intervention (n=16) 
Did not receive allocated intervention 
(declined following allocation, n=1, 
withdrew to seek immediate foot care, n=1) 
Analysed (n=12) 
Lost to follow-up (n=4) 
Self withdrawal (n=3) 
Deceased (n=1) 
Analysed (n=12) 
Lost to follow-up (n=3) 
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regards to incorporating a non-intervention arm.
Acknowledging the limitations of an exploratory trial, the
findings suggest that podiatry-led foot care as a complex
intervention maintains but does not improve foot related
impairment or disability in patients with stable controlled
disease. However, no treatment leads to a small deteriora-
tion in foot health related to impairment but not disabil-
ity.
There were two main challenges to recruitment in this
study-stable drug management and co-morbid disease. As
with all rehabilitation strategies in RA, non-pharmacolog-
ical interventions are adjunct to drug management. With
such powerful effects on symptoms and disease activity
such combinations pose a challenge for outcome evalua-
tion, especially for a disease with natural variation in its
presentation over months and years. On reflection, the
criteria set here for no change in either drug type or dosage
was too stringent. Moreover, choice of medication or dos-
age may be changed for reasons other than controlling the
disease process-tolerance and side-effects for example.
Additionally, the study was based in an outpatient clinic
attached to an academic unit and as such close monitor-
ing of patients may have led to more frequent interven-
tion. For a definitive trial it would be important to gauge
the level of drug monitoring and intervention in other sec-
ondary and primary care settings to help set more prag-
matic exclusion rules. Alternatively the interaction with
between pharmacological and non-pharmacological
treatments and changes in disease severity could be han-
dled by statistical analyses or minimised between groups
although these are difficult to anticipate. How this prob-
lem is handled in other non-pharmacological trials in RA
is not well documented.
Co-morbid disease excluded one fifth of patients
approached for this study, the main reasons being diabe-
tes mellitus and peripheral vascular disease. However,
exclusion was not based on diagnosis alone and was lim-
Table 1: Baseline characteristics of patients by allocation
Demographics and disease 
characteristics
No 
intervention
Podiatry
N1 8 1 6
Female: n (%) 13 (72%) 12 (75%)
Age: years (SD) 64.6 (12.1) 56.8 (10.2)
Disease duration: years (SD) 16.7 (10.1) 14.1 (11.9)
DAS (0–10): median score (IQR) 4.3 (3.5,5.2) 3.7 (3.1,4.2)
HAQ score (0–3): median score 
(IQR)
1.04 (0.48,1.71) 0.75 (0.63,1.13)
BMI: median score (IQR) 27.0 (22.6,32.3) 27.0 (24.8,30.5)
Pharmacological 
management
Analgesics: n (%) 8 (44%) 6 (38%)
NSAIDs: n (%) 9 (50%) 8 (50%)
DMARDs: n (%) 12 (67%) 14 (88%)
Biologic agent: n (%) 2 (11%) 1 (6%)
Corticosteroid: n (%) 5 (28%) 4 (25%)
Other: n (%) 2 (11%) 2 (13%)
Foot disease
LFISIF (0–21): median score (IQR) 13 (12,14) 15 (12,16)
LFISAP (0–30) median score 
(IQR)
21 (16,26) 17 (15,24)
Function
Walking speed (m/s): median 
score (IQR)
0.70 (0.40,1.09) 0.88 (0.76,1.00)
DAS, Disease Activity Score; HAQ, Health Assessment 
Questionnaire; BMI, Body Mass Index; NSAIDs, Non-Steroidal Anti 
Inflammatory Drugs; DMARDs, Disease Modifying Anti-Rheumatic 
Drugs, LFIS, Leeds Foot Impairment Score (IF, Impairment/footwear 
subscale, AP, Activity limitation/participation restriction subscale). 
Values are presented as mean (standard deviation) or median (inter-
quartile range).
Table 2: Change in primary and secondary outcomes between baseline and 12 months.
Podiatry care (n = 16) No podiatry care (n = 18)
Outcome Change BL-12M Change BL-12M Difference (95% CI)* p value
LFISIF (0–21) 0 (-3,1) 1 (0,3) 2 (0 to 4) 0.035
LFISAP (0–30) 0 (-4,2) 0 (-2,1) 0 (-2 to 3) 0.971
DAS (0–10) 0.2 (0,0.5) 0 (0,0.8) 0 (-0.4 to 0.4) 0.791
HAQ (0–3) 0 (-0.03,0) 0 (0,0.25) 0 (-0.12 to 0.33) 0.303
Walking speed (m/s) 0.01 (-0.01,0.07) -0.02 (-0.20,0.02) 0 (-0.1 to 0) 0.411
LFIS, Leeds Foot Impairment Score (IF, Impairment/footwear subscale, AP, Activity limitation/participation restriction subscale); DAS, Disease 
Activity Score; HAQ, Health Assessment Questionnaire; BL-12M, change in score between baseline and 12 months; CI, confidence interval. Values 
for the change in score from BL-12M are presented as the median (inter-quartile range). The between group difference in change scores was based 
on the Hodges-Lehman estimate of the median difference with 95% confidence interval based on a two-sided Mann-Whitney U-test.BMC Musculoskeletal Disorders 2007, 8:109 http://www.biomedcentral.com/1471-2474/8/109
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ited to those who were at risk from developing foot-
related complications, primarily infection and foot ulcer-
ation. In reality most of these patients were excluded as
they were in receipt of foot care or assessment/advice in
other specialist clinics such as the hospital diabetic foot
clinic. Exclusion by co-morbid disease requires more pre-
cise definition in future trials and should look beyond
diagnosis and towards related complications and second-
ary treatment.
We found that over one-third of patients refused to partic-
ipate in the trial. Our main concern was the use of a non-
intervention arm. However, additional visits to clinic (as
raised in the patient focus group), lack of perceived under-
standing of role and the benefit/risks of podiatry care were
the three most common reasons for refusal. Indeed only
one patient declined following allocation to the non-
intervention group to seek care and this was matched by
one patient in the intervention arm who did not want
additional hospital visits. Organisations such as the
Arthritis Research Campaign provide leaflets specifically
detailing foot problems and their treatment but availabil-
ity in outpatient clinics and uptake is not known. These
findings indicate that in a definitive trial, like any new or
novel treatment, the potential benefits and hazards of
podiatry-led foot care must be fully explained during the
recruitment of patients before they make an informed
choice. Throughout the trial we were encouraged that loss
to follow up was comparable between groups with no
strong evidence of resentful demoralisation (deliberate
withdrawal of patients in the control group who perceive
differential benefit for the intervention group).
The findings suggest that a non-treatment parallel arm can
also be used in a definitive trial. However, other
approaches such as a patient preference design or unequal
randomisation, e.g., 2:1 in favour of receiving the inter-
vention, could improve recruitment [20]. Alternatives,
such as a minimal or sham intervention arm, for example
using an information leaflet or sham insole, could also be
considered. However, sham procedures are not suitable
within pragmatic trials as they do not model usual prac-
tice. Furthermore, sham physical agents mimicking inter-
ventions such as scalpel debridement and foot orthotics
may have physiological effects that are therapeutic [11].
Indeed, we have encountered this problem in a previous
trial and do not favour this approach [11].
In this exploratory trial the groups were well balanced at
baseline for all but one demographic or disease variable
indicating that the automated randomisation worked and
was feasible for this type of study. In a definitive trial, we
suggest the use of minimisation – where patients are allo-
cated to a particular treatment depending on the charac-
teristics of those participants already enrolled.
Minimisation ensures excellent balance across important
prognostic factors and is recommended for small trials
[21]. Factors to minimise imbalance should include age,
gender, disease duration, and disease severity.
Significant variation in the type and frequency of podiatry
interventions was not an unexpected finding for an
exploratory trial with a pragmatic design. However, this
approach revealed important factors about the delivery of
podiatry care. For example, the definition of the start of
treatment was imprecise since patients frequently received
an initial assessment consultation and then further
appointments during the work up to a physical interven-
tion such as customised orthoses. Notwithstanding the
potential non-specific benefits from these consultations,
the main physical treatment was often started some
months later from baseline assessment. In the present
study we also underestimated the 'gatekeeper' role of
podiatrist as the rates of referral to other experts was much
higher than expected. The extent to which these findings
represents local practice or are generalisable to secondary
care provision in the UK is unclear. However, with a lack
of care pathways and published clinical guidelines further
modelling, as suggested in the preclinical and phase I
stages of the MRC framework, is required in other centres
to define more precisely the constituent parts of podiatry
care as well as the extent of other medical, allied health,
surgical and self-care involvement. This potential lack of
standardisation represents a significant challenge should
a definitive trial remain pragmatic and expanded to multi-
centre design.
The LFIS provides us with a well-validated patient-focused
outcome for use in this type of trial [19]. In an exploratory
analysis we detected no change in foot-related impair-
ment and disability and slight deterioration in impair-
ment in the intervention and no interventions groups
respectively. This was observed against a backdrop of sta-
ble, well-controlled disease. The study was not adequately
powered for this outcome but the data generated here and
in other pilot studies in our unit will beneficially inform a
robust sample size calculation for a definitive trial. For
example, based on (previously unreported) data from 141
cases for the primary outcome of LFISIF, a minimally clin-
ically important difference would be 3 points with a
standard deviation of 5 points. For a two treatment paral-
lel-design RCT of podiatry-led foot care versus no foot
care, 85 per group would be required to detect a difference
between the groups of 3 point, based on 90% power and
1% significance level. According to figures from this pilot,
a 20% loss to follow-up would be expected so a total sam-
ple size of 102 per arm would be required.
Embedded within in a definitive trial should be a qualita-
tive study appraising patient's perceptions and beliefsBMC Musculoskeletal Disorders 2007, 8:109 http://www.biomedcentral.com/1471-2474/8/109
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about their foot care experiences. Efficacy and side-effects
are important factors in the evolving experience of RA
patients treated pharmacologically, for example with
DMARD therapy [22]. Our focus group work revealed low
expectation and lack of outcome may have been influ-
enced by poor understanding of the role of podiatry; prior
experience from home or over-the-counter remedies such
as insoles, foot spas and creams; the inconvenience of
additional hospital visits; and lack of benefit gained over
the 12 month treatment period. Referring to the MRC
framework, the findings from RheumAFooT suggest that
further phase I modelling is required as well as refinement
to the design of a definitive trial.
Conclusion
There are increasing calls for foot care to be made more
widely available to patients with RA and these are appear-
ing in important clinical guidelines and reports
[7,8,12,15,2]. However, podiatry-led care is a complex
and complicated intervention and no evidence exists to
support its use in these patients. Based on the MRC frame-
work, this exploratory trial has provided useful data to
guide the development and implementation of a phase III
definitive RCT.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
DET conceived of the study, planned the protocol, organ-
ised and conducted patient focus groups, and undertook
recruitment and clinical data collection
PSH conceived of the study and secured funding, partici-
pated in the planning of the study and provided expert
advice during data collection and analysis.
JW conceived of the study and secured funding, coordi-
nated the ethical approval, coordinated the trial manage-
ment group, planned the protocol and conducted the
analyses.
All authors read and approved the final manuscript
Acknowledgements
The authors would like to thank the patients and staff of the rheumatology 
outpatient Clinic at the Leeds General Infirmary, Leeds, UK for their help 
and support. The work of Prof. Woodburn was funded by a UK Medical 
Research Council Clinician Scientist Fellowship. The funding body had no 
role in study design, conduct of the study, data interpretation, reporting the 
data or decision to submit the manuscript for publication.
References
1. Scott DL: Early rheumatoid arthritis.  Br Med Bull 2007,
81–82:97-114.
2. Williams AE, Bowden AP: Meeting the challenge for foot health
in rheumatic diseases.  The Foot 2004, 14:154-8.
3. Matricali GA, Boonen A, Verduyckt J, Taelman V, Vershueren P,
Sileghem A, Corluy L, Westhovens R: The presence of forefoot
problems and the role of surgery in patients with rheuma-
toid arthritis.  Ann Rheum Dis 2006, 65:1254-5.
4. Minaker K, Little H: Painful feet in rheumatoid arthritis.  Can
Med Assoc J 1973, 109(8):724-725.
5. Turner DE, Helliwell PS, Emery P, Woodburn J: The impact of
rheumatoid arthritis on foot function in the early stages of
disease: a clinical case series.  BMC Musculoskelet Disord 7:102.
2006 Dec 21;
6. Wickman AM, Pinzur MS, Kadanoff R, Juknelis D: Health-related
quality of life for patients with rheumatoid arthritis foot
involvement.  Foot Ankle Int 2004, 25:19-26.
7. Korda J, Balint GP: When to consult the podiatrist.  Best Pract Res
Clin Rheumatol 2004, 18:587-611.
8. Gossec L, Pavy S, Pharm T, Constantin A, Poiraudeau S, Combe B,
Flipo RM, Goupille P, Le Loet X, Mariette X, Puechal X, Wendling D,
Schaeverbeke T, Sibilia J, Tebib J, Cantagrel A, Dougados M: Nonp-
harmacological treatments in early rheumatoid arthritis:
clinical practice guidelines based on published evidence and
expert opinion.  Joint Bone Spine 2006, 73:396-402.
9. Chalmers AC, Busby C, Goyert J, Porter B, Schlzer M: Metatarsal-
gia and rheumatoid arthritis: a randomised single-blind,
sequential trial comparing 2 types of foot orthoses and sup-
portive shoes.  J Rheumatol 2000, 27:1643-7.
10. Williams AE, Rome K, Nester CJ: a clinical trial of specialist foot-
wear for patients with rheumatoid arthritis.  Rheumatology
2007, 46:302-7.
11. Davys HJ, Turner DE, Helliwell PS, Conaghan PG, Emery P, Wood-
burn J: Debridement of plantar callosities in rheumatoid
arthritis: a randomized controlled trial.  Rheumatology 2005,
44:207-210.
12. Redmond AC, Waxman R, Helliwell PS: Provision of foot health
services in rheumatology.  Rheumatology 2006, 45:571-6.
13. Martin LJ, Griffith SM: High disease activity scores predict the
need for additional health services in patients over 60 with
rheumatoid arthritis.  Musculoskelet Care 2006, 4:1-11.
14. Farrow SJ, Kingsley GH, Scott DL: Interventions for foot disease
in rheumatoid arthritis: a systematic review.  Arthritis Rheum
2005, 53:593-602.
15. Woodburn J, Helliwell P: Foot problems in rheumatology.  Br J
Rheumatol 1997, 36:932-4.
16. Medical Research Council: A framework for development and
evaluation of RCTs for complex interventions to improve
health.  Medical Research Council; 2000. 
17. Arnett FC, Edworthy SM, Bloch DA, Mcshane DJ, Fries JF, Cooper
NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA Jr,
Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder
RL, Hunder GS: The American Rheumatism Association 1987
revised criteria for the classification of rheumatoid arthritis.
Arthritis Rheum 1988, 31:315-24.
18. Helliwell PS, Allen N, Gilworth G, Redmond A, Slade A, Tennant A,
Woodburn J: Development of a foot impact scale for rheuma-
toid arthritis.  Arthritis Rheum 2005, 53:418-22.
19. Ward E, King M, Lloyd M, Bower P, Friedli K: Conducting rand-
omized trials in general practice: methodological and practi-
cal issues.  Br J Gen Pract 1999, 49(448):919-922.
20. Altman DG, Bland JM: Treatment allocation by minimisation.
BMJ 2005, 330:843.
21. Goodacre LJ, Goodacre JA: Factors influencing the beliefs of
patients with rheumatoid arthritis regarding disease-modify-
ing medication.  Rheumatology 2004, 43:583-6.
22. Scottish Intercollegiate Guidelines Network (SIGN): Management
of Early Rheumatoid Arthritis. A National Clinical Guideline.
SIGN publication No. 48 2000.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2474/8/109/pre
pub